Progesterone-Only Transdermal Patches: Current Availability
There are currently no progesterone-only transdermal patches approved by the FDA or comparable regulatory bodies for endometrial protection in menopausal hormone therapy. 1
Key Evidence on Transdermal Progesterone
The Endocrine Society Clinical Practice Guideline explicitly states that clinicians can administer progestogen orally, transdermally by patch, vaginally, or by intrauterine administration 1. However, this statement refers to theoretical routes of administration rather than actual FDA-approved products.
Critical Limitation: Lack of Endometrial Protection
Transdermal micronized progesterone does not provide endometrial protection 2. This is a crucial safety concern for women with an intact uterus using estrogen therapy, as they require adequate progestogen to prevent endometrial hyperplasia and cancer 1.
Available Progesterone Formulations
While progesterone-only patches are not available, the following FDA-approved progesterone formulations can be used:
Oral Options
- Micronized progesterone 200 mg/day for 12-14 days/month (sequential) provides endometrial protection for up to 5 years 2
- Oral synthetic progestogens (medroxyprogesterone acetate, norethindrone acetate) are effective for vasomotor symptoms 1
Vaginal Options (Off-Label)
- Vaginal micronized progesterone 4% gel (45 mg/day) or 100 mg every other day for at least 10 days/month may provide endometrial protection for 3-5 years 2
Intrauterine Option
- Levonorgestrel intrauterine device minimizes systemic absorption, though increased blood levels do occur 1
Important Caveats
The guideline strongly recommends using only FDA-approved preparations and avoiding custom-compounded hormones 1. Custom-compounded progesterone lacks FDA oversight, and clinical trials documenting efficacy and safety for endometrial protection are absent.
Combination Patches Available
Note that combination estrogen-progestogen patches exist (containing estradiol with norethindrone acetate or levonorgestrel), but these are not progesterone-only formulations 3.
Research Pipeline
Recent research (2026) describes experimental compound estradiol-progesterone patches in development 4, but these remain investigational and are not clinically available.
Clinical Bottom Line
For a perimenopausal woman with an intact uterus requiring progesterone for endometrial protection, oral micronized progesterone 200 mg/day remains the preferred bioidentical option, as transdermal progesterone formulations either don't exist as approved products or fail to provide adequate endometrial protection 1, 2.